FDA Approves Alcon's Travatan Z for Glaucoma and Angular Hypertension
Alcon Inc (ACL) announced today that the FDA has approved Travatan Z solution for the reduction of intra-ocular pressure in glaucoma and angular hypertenive patients.
Travatan Z is a new formulation of Alcon's existing Travatan solution but without the preservative benzalkonium chloride (BAK), which may cause dry eye and other unwanted conditions with regular use. Travatan Z is formulated with the preservative SOFIA(TM) that has been shown to be more gentle on the ocular surface.
Shares of Alcon gained 0.31% to end trading at $116.00 a share. Alcon stock has been on a tremendous pace ever since its IPO in March of 2002 closing its first ever day of trading at $34.75.
_
Alcon Inc (ACL) announced today that the FDA has approved Travatan Z solution for the reduction of intra-ocular pressure in glaucoma and angular hypertenive patients.
Travatan Z is a new formulation of Alcon's existing Travatan solution but without the preservative benzalkonium chloride (BAK), which may cause dry eye and other unwanted conditions with regular use. Travatan Z is formulated with the preservative SOFIA(TM) that has been shown to be more gentle on the ocular surface.
Shares of Alcon gained 0.31% to end trading at $116.00 a share. Alcon stock has been on a tremendous pace ever since its IPO in March of 2002 closing its first ever day of trading at $34.75.
_
posted by Nico at
10:19 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home